Form 4: Karyopharm Therapeutics CEO Richard Paulson Receives Stock Options and Restricted Stock Units

Richard Paulson, CEO of Karyopharm Therapeutics, was granted stock options and restricted stock units (RSUs) on February 28, 2025, according to a Form 4 filing.

Summary

• Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., received an award of 20,000 restricted stock units (RSUs) on February 28, 2025.
• These RSUs, granted under the company's 2022 Equity Incentive Plan, will convert into common stock on a one-for-one basis.
• The RSUs vest in three equal annual installments starting February 28, 2026.
• Paulson also received a stock option to purchase 40,000 shares of common stock at an exercise price of $7.95.
• This option, also granted on February 28, 2025, vests as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
• The filing reflects a one-for-fifteen reverse stock split that Karyopharm Therapeutics Inc. effected on February 25, 2025.
• Following the reported transactions, Paulson beneficially owns 94,678 shares of common stock and 40,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity compensation is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. The reverse stock split is a neutral event, often done to maintain listing requirements.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedules for both the RSUs and stock options incentivize long-term performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top talent and align their interests with those of shareholders. The size and structure of the grants are typical for a CEO of a publicly traded company.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded biotech companies.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to incentivize their leadership.
• The vesting schedules described are typical, with vesting occurring over a period of several years to encourage long-term commitment.

Stakeholder Impact

• The equity grants incentivize the CEO to increase shareholder value.
• Employees may be indirectly impacted by the CEO's performance.

Key Dates

Keywords

Karyopharm Therapeutics, Richard Paulson, CEO, stock options, restricted stock units, RSUs, Form 4, equity incentive plan, reverse stock split, beneficial ownership